Study guide

4.1 Autonomic and Central Nervous System Pharmacology

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

4.1 Autonomic and Central Nervous System Pharmacology

Key Takeaways Explain This Topic AI

Autonomic signal transduction is governed by distinct G-protein coupled cascades: Gq (alpha-1, M1, M3, M5) activates PLC/IP3/DAG; Gi (alpha-2, M2, M4) inhibits adenylyl cyclase and lowers cAMP; Gs (beta-1, beta-2, beta-3, D1) stimulates adenylyl cyclase and elevates cAMP.

Cardioselective beta-1 blockers (e.g., bisoprolol, metoprolol, atenolol) spare beta-2 bronchial receptors at therapeutic doses, whereas non-selective agents (propranolol, nadolol) and intrinsic sympathomimetic activity (ISA) agents (pindolol, acebutolol) have distinct hemodynamic and pulmonary profiles.

GABA-A receptors are pentameric ligand-gated chloride channels where benzodiazepines increase channel opening frequency, while barbiturates prolong open duration; Z-drugs selectively target the alpha-1 subunit for sedative-hypnotic efficacy.

Second-generation antipsychotics combine dopamine D2 receptor antagonism with serotonin 5-HT2A antagonism, lowering extrapyramidal symptom (EPS) risks but increasing metabolic liabilities; clozapine requires strict absolute neutrophil count (ANC) hematologic surveillance due to agranulocytosis risk.

Antiseizure medications act through targeted molecular mechanisms: voltage-gated sodium channel inactivation (phenytoin, carbamazepine, lamotrigine), T-type calcium channel inhibition in thalamocortical neurons (ethosuximide for absence seizures), GABAergic potentiation (valproate, clobazam), and SV2A vesicle binding (levetiracetam).

Last updated: August 2026

4.1 Autonomic and Central Nervous System Pharmacology

The autonomic nervous system (ANS) and central nervous system (CNS) coordinate involuntary physiological homeostasis, neuroendocrine regulation, cognition, and motor control. A thorough mastery of receptor subtype signaling, neurotransmitter life cycles, and neuropharmacological drug actions is a foundational core of the PEBC Evaluating Examination.

1. Autonomic Nervous System Organization and Signal Transduction

The ANS comprises the sympathetic (thoracolumbar) and parasympathetic (craniosacral) divisions, functioning through distinct preganglionic and postganglionic neurotransmitters and receptor superfamilies. +--------------------------------------------------------------------------------------+

  • | AUTONOMIC NEUROTRANSMISSION PATHWAYS |
  • +--------------------------------------------------------------------------------------+
  • | PARASYMPATHETIC: |
  • | [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(ACh)===> [Effector Muscarinic (M)] |
  • | |
  • | SYMPATHETIC: |
  • | [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(NE)===> [Effector Adrenoceptors] |
  • | | (alpha-1, beta-1, beta-2) |
  • | +===(ACh)===> [Sweat Glands (M3)] |
  • | +===(DA)===> [Renal Vasculature(D1)]|
  • | |
  • | ADRENAL MEDULLA: |
  • | [CNS] ===(ACh)===> [Chromaffin Cell Nn] ===> [Epinephrine (80%) + NE (20%) in Blood]|
  • | |
  • | SOMATIC MOTOR: |
  • | [CNS Motoneuron] =========================(ACh)=========================> [Nm / NMJ]|
  • +--------------------------------------------------------------------------------------+
  • Adrenoceptor Subtypes and G-Protein Coupling

Adrenoceptors are 7-transmembrane G-protein coupled receptors (GPCRs) responsive to endogenous catecholamines (norepinephrine and epinephrine): G q Coupling ( α 1 ) ⟹ ↑ Phospholipase C (PLC) → ↑ IP 3 + DAG → ↑ [ Ca 2 + ] i → Smooth Muscle Contraction G i Coupling ( α 2 ) ⟹ ↓ Adenylyl Cyclase (AC) → ↓ cAMP + ↓ PKA → Inhibition of Transmitter Release G s Coupling ( β 1 , β 2 , β 3 ) ⟹ ↑ Adenylyl Cyclase (AC) → ↑ cAMP → ↑ Protein Kinase A (PKA) \begin{aligned}

\mathbf{G_q \text{ Coupling (}\alpha_1\text{)}} &\implies \uparrow \text{Phospholipase C (PLC)} \to \uparrow \text{IP}_3 + \text{DAG} \to \uparrow [\text{Ca}^{2+}]_i \to \text{Smooth Muscle Contraction} \\

\mathbf{G_i \text{ Coupling (}\alpha_2\text{)}} &\implies \downarrow \text{Adenylyl Cyclase (AC)} \to \downarrow \text{cAMP} + \downarrow \text{PKA} \to \text{Inhibition of Transmitter Release} \\

\mathbf{G_s \text{ Coupling (}\beta_1, \beta_2, \beta_3\text{)}} &\implies \uparrow \text{Adenylyl Cyclase (AC)} \to \uparrow \text{cAMP} \to \uparrow \text{Protein Kinase A (PKA)}

\end{aligned} G q ​ Coupling ( α 1 ​ ) G i ​ Coupling ( α 2 ​ ) G s ​ Coupling ( β 1 ​ , β 2 ​ , β 3 ​ ) ​ ⟹ ↑ Phospholipase C (PLC) →↑ IP 3 ​ + DAG →↑ [ Ca 2 + ] i ​ → Smooth Muscle Contraction ⟹ ↓ Adenylyl Cyclase (AC) →↓ cAMP + ↓ PKA → Inhibition of Transmitter Release ⟹ ↑ Adenylyl Cyclase (AC) →↑ cAMP →↑ Protein Kinase A (PKA) ​

Receptor Subtype Primary G-Protein Key Anatomical Locations Primary Physiological Effect Clinical Agonists / Antagonists

α 1 \alpha_1 α 1 ​ G q G_q G q ​ Vascular smooth muscle, radial pupillary muscle, prostate, bladder neck Vasoconstriction ( ↑ \uparrow ↑ SVR, ↑ \uparrow ↑ BP), mydriasis, urinary sphincter contraction Agonists: Phenylephrine, midodrine. Antagonists: Prazosin, doxazosin, tamsulosin ( α 1 A \alpha_{1A} α 1 A ​ selective)

α 2 \alpha_2 α 2 ​ G i G_i G i ​ Presynaptic adrenergic terminals, pancreatic β \beta β -cells, CNS brainstem ↓ \downarrow ↓ NE release (negative feedback), ↓ \downarrow ↓ sympathetic outflow, ↓ \downarrow ↓ insulin secretion Agonists: Clonidine, apraclonidine, dexmedetomidine. Antagonists: Yohimbine

β 1 \beta_1 β 1 ​ G s G_s G s ​ Myocardium (SA/AV node, ventricular myocytes), juxtaglomerular cells ↑ \uparrow ↑ Heart rate (chronotropy), ↑ \uparrow ↑ contractility (inotropy), ↑ \uparrow ↑ AV conduction (dromotropy), ↑ \uparrow ↑ renin release Agonists: Dobutamine, isoproterenol. Antagonists: Bisoprolol, metoprolol, atenolol, esmolol

β 2 \beta_2 β 2 ​ G s G_s G s ​ Bronchial smooth muscle, skeletal vascular beds, uterine muscle, liver Bronchodilation, vasodilation, uterine relaxation (tocolysis), ↑ \uparrow ↑ glycogenolysis, ↑ K + \uparrow \text{K}^+ ↑ K + cellular uptake Agonists: Salbutamol, formoterol, salmeterol, terbutaline. Antagonists: Propranolol, timolol, nadolol

β 3 \beta_3 β 3 ​ G s G_s G s ​ Adipose tissue, detrusor smooth muscle of urinary bladder ↑ \uparrow ↑ Lipolysis, detrusor relaxation (increases bladder storage capacity) Agonists: Mirabegron, vibegron

Cholinergic Receptors: Muscarinic and Nicotinic Subtypes

Muscarinic GPCRs :

M 1 , M 3 , M 5 M_1, M_3, M_5 M 1 ​ , M 3 ​ , M 5 ​ ( G q G_q G q ​ ) : Mediate exocrine glandular secretion (salivation, lacrimation, sweating), gastrointestinal smooth muscle contraction, bronchial constriction, and pupillary sphincter contraction (miosis). M 3 M_3 M 3 ​ stimulation on vascular endothelial cells stimulates endothelial nitric oxide synthase (eNOS), releasing nitric oxide (NO) and causing paradoxical vasodilation.

M 2 , M 4 M_2, M_4 M 2 ​ , M 4 ​ ( G i G_i G i ​ ) : M 2 M_2 M 2 ​ receptors are localized on the sinoatrial and atrioventricular nodes, opening inward-rectifying K + \text{K}^+ K + channels ( I K , ACh I_{K,\text{ACh}} I K , ACh ​ ) and decreasing cAMP, producing negative chronotropy, negative dromotropy, and decreased atrial inotropy.

Nicotinic Ligand-Gated Ion Channels :

N M N_M N M ​ (Neuromuscular junction) : Pentameric ( α 1 ) 2 β 1 γ δ (\alpha_1)_2\beta_1\gamma\delta ( α 1 ​ ) 2 ​ β 1 ​ γ δ ion channels. Acetylcholine binding allows rapid Na + \text{Na}^+ Na + influx and K + \text{K}^+ K + efflux, causing endplate potential depolarization and skeletal muscle contraction.

N N N_N N N ​ (Autonomic ganglia and adrenal medulla) : Mediates trans-synaptic transmission across all autonomic ganglia.

2. Autonomic Pharmacology: Therapeutic Drug Classes +--------------------------------------------------------------------------------------+

  • | AUTONOMIC DRUG CLASSIFICATION MATRIX |
  • +--------------------------------------------------------------------------------------+
  • | CHOLINERGIC AGENTS: |
  • | - Direct Agonists : Bethanechol (bladder atony), Pilocarpine (glaucoma) |
  • | - AChE Inhibitors : Donepezil, Rivastigmine, Pyridostigmine, Neostigmine |
  • | - Antimuscarinics : Atropine, Ipratropium, Tiotropium, Oxybutynin, Glycopyrrolate|
  • | |
  • | ADRENERGIC AGENTS: |
  • | - Non-Selective Agonists: Epinephrine (alpha-1, alpha-2, beta-1, beta-2), NE |
  • | - Beta-Blockers (Selective): Bisoprolol, Metoprolol, Atenolol (Cardioselective) |
  • | - Beta-Blockers (Non-Sel): Propranolol, Timolol, Nadolol |
  • | - Alpha-Beta Blockers : Carvedilol, Labetalol |
  • | - Alpha-1 Blockers : Tamsulosin (BPH), Prazosin, Doxazosin (Antihypertensive) |
  • +--------------------------------------------------------------------------------------+
  • Neuromuscular Blockers and Reversal Strategies

Depolarizing Blockers (Succinylcholine) : Binds N M N_M N M ​ receptors and causes persistent endplate depolarization (Phase I block with fasciculations, followed by Phase II desensitization block). Rapid onset ( < 60 seconds <60\text{ seconds} < 60 seconds ), ultra-short duration ( 5 − 10 minutes 5-10\text{ minutes} 5 − 10 minutes ) metabolized by plasma butyrylcholinesterase (pseudocholinesterase). Adverse effects : Hyperkalemia (hazardous in burn, trauma, or spinal denervation patients due to extrajunctional receptor upregulation), malignant hyperthermia (treated with dantrolene ), and prolonged apnea in atypical pseudocholinesterase variants.

Non-Depolarizing Blockers (Rocuronium, Vecuronium, Cisatracurium) : Competitive antagonists at N M N_M N M ​ receptors. Cisatracurium undergoes organ-independent Hofmann elimination (spontaneous ester hydrolysis and chemical degradation at physiological pH and temperature), making it the agent of choice in severe renal or hepatic impairment.

Reversal Agents :

Sugammadex : A modified gamma-cyclodextrin that encapsulates and chelates aminosteroid blockers (rocuronium > > > vecuronium) in plasma at a 1:1 molar ratio, achieving rapid, chemically specific reversal independent of cholinesterase inhibition.

Neostigmine + Glycopyrrolate : Neostigmine inhibits AChE to elevate synaptic ACh and competitively displace the blocker; co-administered glycopyrrolate or atropine prevents muscarinic side effects (profound bradycardia, bronchospasm, hypersalivation).

  • 3. Central Nervous System Pharmacology: Neurotransmitters and Affective Disorders
  • GABAergic and Glutamatergic Neurotransmission [GABA-A Receptor: Chloride Ionophore]
  • +---------------------------------+
  • | Benzodiazepine Site (alpha/gamma)|
  • | GABA Agonist Site (alpha/beta) |
  • | Barbiturate Site (Transmembrane) |
  • | Picrotoxin / Channel Pore |
  • +---------------------------------+
  • |
  • +------------------------+------------------------+
  • | |
  • v v
  • [Benzodiazepines: Increase Frequency] [Barbiturates: Increase Duration]
  • Shift GABA curve to the left - Direct opening at high doses
  • Flumazenil competitive antagonist - Lower safety margin, respiratory arrest

GABA A \text{GABA}_A GABA A ​ Receptor Modulators :

Benzodiazepines (Lorazepam, Diazepam, Clonazepam) : Bind allosterically to the α / γ \alpha/\gamma α / γ subunit interface, increasing the frequency of channel opening in response to GABA. Indicated for acute anxiety, panic disorder, alcohol withdrawal, and status epilepticus.

Barbiturates (Phenobarbital, Thiopental) : Increase the duration of chloride channel opening and can directly open chloride channels at high concentrations without GABA, explaining their narrow therapeutic index and fatal respiratory depression risks.

Z-Drugs (Zopiclone, Zolpidem) : Selective positive allosteric modulators at α 1 \alpha_1 α 1 ​ -containing GABA A \text{GABA}_A GABA A ​ complexes, delivering hypnotic action with minimal anxiolytic or muscle relaxant effects.

GABA B \text{GABA}_B GABA B ​ Receptor Agonist (Baclofen) : Presynaptic G i G_i G i ​ -coupled GPCR that increases K + \text{K}^+ K + conductance, hyperpolarizing motor neurons and relieving muscle spasticity.

Antidepressant Pharmacotherapy (CANMAT Guidelines)

According to the Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for Major Depressive Disorder (MDD):

Antidepressant Class Representative Agents Primary Mechanism High-Yield Clinical Pearls & Adverse Effects

SSRIs Escitalopram, Sertraline, Fluoxetine, Paroxetine, Citalopram Selective inhibition of presynaptic Serotonin Transporter (SERT) First-line MDD; GI upset, sexual dysfunction, insomnia, hyponatremia (SIADH in elderly), QTc prolongation (citalopram max 40 mg/day 40\text{ mg/day} 40 mg/day , 20 mg/day 20\text{ mg/day} 20 mg/day if > 60 years >60\text{ years} > 60 years ). Fluoxetine/paroxetine potently inhibit CYP2D6.

SNRIs Venlafaxine, Duloxetine, Desvenlafaxine Dual inhibition of SERT and Norepinephrine Transporter (NET) First-line MDD and neuropathic pain (duloxetine); dose-dependent diastolic hypertension (venlafaxine), discontinuation syndrome upon abrupt cessation.

Atypical / Multimodal Bupropion, Mirtazapine, Vortioxetine Bupropion: NET and DAT blocker; Mirtazapine: presynaptic α 2 \alpha_2 α 2 ​ blocker + 5 -HT 2 / 5 -HT 3 / H 1 5\text{-HT}_2 / 5\text{-HT}_3 / H_1 5 -HT 2 ​ /5 -HT 3 ​ / H 1 ​ antagonist Bupropion: zero sexual dysfunction, aids smoking cessation, lowers seizure threshold (contraindicated in bulimia/anorexia). Mirtazapine: sedation, marked appetite stimulation and weight gain.

TCAs Amitriptyline, Nortriptyline, Clomipramine Non-selective SERT/NET blockade + antagonist at H 1 H_1 H 1 ​ , α 1 \alpha_1 α 1 ​ , M 1 M_1 M 1 ​ , and cardiac fast I Na I_{\text{Na}} I Na ​ Fatal in overdose due to cardiac conduction blocks, refractory ventricular arrhythmias (prolonged QRS), and hypotension; anticholinergic toxidrome. Clomipramine is gold standard for refractory OCD.

MAOIs Phenelzine, Tranylcypromine, Moclobemide (RIMA) Irreversible non-selective MAO-A/B inhibition (phenelzine) or reversible MAO-A inhibition (moclobemide) Hypertensive crisis when combined with tyramine-rich foods (aged cheeses, draft beers, cured meats). Mandatory 14 -day 14\text{-day} 14 -day washout when switching to/from other serotonergic agents ( 5 weeks 5\text{ weeks} 5 weeks for fluoxetine).

4. Antipsychotic Pharmacotherapy and Extrapyramidal Syndromes +--------------------------------------------------------------------------------------+

  • | DOPAMINE PATHWAYS IN ANTIPSYCHOTIC PHARMACOLOGY |
  • +--------------------------------------------------------------------------------------+
  • | 1. Mesolimbic Pathway : Excess DA = Positive symptoms; D2 block = Antipsychotic |
  • | 2. Mesocortical Pathway : Deficient DA = Negative/cognitive symptoms |
  • | 3. Nigrostriatal Pathway : D2 block = Extrapyramidal Symptoms (EPS) and Tardive Dysk|
  • | 4. Tuberoinfundibular : D2 block = Hyperprolactinemia (galactorrhea, amenorrhea)|
  • +--------------------------------------------------------------------------------------+
  • First-Generation (Typical) vs. Second-Generation (Atypical) Antipsychotics

First-Generation Antipsychotics (FGAs: Haloperidol, Fluphenazine, Chlorpromazine) : High-affinity competitive antagonists at dopamine D 2 D_2 D 2 ​ receptors. High-potency agents (haloperidol) carry high rates of extrapyramidal symptoms (EPS) and hyperprolactinemia, but low anticholinergic/sedative liabilities.

Second-Generation Antipsychotics (SGAs: Olanzapine, Risperidone, Quetiapine, Aripiprazole, Clozapine) : Combine D 2 D_2 D 2 ​ antagonism with potent serotonin 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A ​ antagonism . 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A ​ blockade stimulates dopamine release in the nigrostriatal tract, mitigating EPS.

Aripiprazole / Brexpiprazole / Cariprazine : Partial agonists at D 2 D_2 D 2 ​ and 5 -HT 1 A 5\text{-HT}_{1A} 5 -HT 1 A ​ receptors, acting as functional stabilizers with low metabolic and EPS liabilities.

Metabolic Liability Hierarchy : Clozapine = = = Olanzapine > > > Quetiapine ≥ \ge ≥ Risperidone > > > Lurasidone = = = Ziprasidone = = = Aripiprazole.

Extrapyramidal Symptom (EPS) Spectrum and Management

EPS Type Onset Timeline Clinical Features Pharmacological Management

Acute Dystonia Hours to days Involuntary spastic muscle contractions (torticollis, oculogyric crisis, trismus, laryngeal spasm) Anticholinergics: Benztropine ( 1 − 2 mg 1-2\text{ mg} 1 − 2 mg IV/IM) or Diphenhydramine ( 25 − 50 mg 25-50\text{ mg} 25 − 50 mg IV/IM)

Akathisia Days to weeks Subjective motor restlessness, irresistible urge to move lower limbs Propranolol ( 10 − 40 mg 10-40\text{ mg} 10 − 40 mg PO TID) is first-line; dose reduction or switch to quetiapine/aripiprazole

Parkinsonism Weeks to months Bradykinesia, cogwheel rigidity, resting tremor, masked facies Dose reduction, switch to SGA, or add benztropine/amantadine

Tardive Dyskinesia Months to years Involuntary choreoathetoid movements of face, tongue (buccolingual masticatory), or trunk Discontinue anticholinergics; switch to clozapine or quetiapine; VMAT-2 inhibitors ( Valbenazine, Deutetrabenazine )

Neuroleptic Malignant Syndrome (NMS) Any time "Lead-pipe" rigidity, severe hyperthermia, autonomic instability, altered mental status, marked ↑ \uparrow ↑ CK Discontinue antipsychotic immediately; ICU admission; Dantrolene (ryanodine blocker), Bromocriptine (DA agonist)

Clozapine Hematologic Surveillance

Clozapine is the gold standard for treatment-resistant schizophrenia (failure of ≥ 2 \ge 2 ≥ 2 adequate antipsychotic trials). It is non-EPS-inducing but carries risks of agranulocytosis ( < 1 % <1\% < 1% ), severe constipation/ileus, myocarditis, and seizures.

Health Canada and Canadian registry protocols mandate baseline and regular Absolute Neutrophil Count (ANC) monitoring:

Mandatory threshold to initiate: ANC ≥ 2.0 × 10 9 /L \text{ANC} \ge 2.0 \times 10^9\text{/L} ANC ≥ 2.0 × 1 0 9 /L (or ≥ 1.5 × 10 9 /L \ge 1.5 \times 10^9\text{/L} ≥ 1.5 × 1 0 9 /L for Benign Ethnic Neutropenia / BEN).

If ANC < 1.5 × 10 9 /L \text{ANC} < 1.5 \times 10^9\text{/L} ANC < 1.5 × 1 0 9 /L (mild/moderate neutropenia): Interrupt therapy and monitor daily.

If ANC < 1.0 × 10 9 /L \text{ANC} < 1.0 \times 10^9\text{/L} ANC < 1.0 × 1 0 9 /L (severe agranulocytosis): Immediately and permanently discontinue clozapine.

5. Antiseizure Medications (ASMs) and Parkinson's Disease Pharmacotherapy +--------------------------------------------------------------------------------------+

  • | ANTISEIZURE MEDICATIONS MECHANISM MATRIX |
  • +--------------------------------------------------------------------------------------+
  • | 1. Voltage-Gated Na+ Channel Blockers: Phenytoin, Carbamazepine, Lamotrigine, Lacosamide
  • | 2. T-Type Ca2+ Channel Blockers : Ethosuximide (Selective for Absence Seizures) |
  • | 3. Alpha-2-Delta Ca2+ Ligands : Gabapentin, Pregabalin (Neuropathic Pain/Adjunct)
  • | 4. SV2A Vesicular Protein Modulators: Levetiracetam, Brivaracetam |
  • | 5. GABAergic Potentiators : Valproic Acid, Clobazam, Vigabatrin, Tiagabine|
  • | 6. Broad-Spectrum Mixed Actions : Valproic Acid, Topiramate, Zonisamide |
  • +--------------------------------------------------------------------------------------+

Phenytoin : Displays non-linear Michaelis-Menten pharmacokinetics (hepatic CYP2C9/2C19 saturation within therapeutic range 40 − 80 μ mol/L 40-80\text{ }\mu\text{mol/L} 40 − 80 μ mol/L [ 10 − 20 mg/L 10-20\text{ mg/L} 10 − 20 mg/L ]). Chronic adverse effects: gingival hyperplasia, hirsutism, peripheral neuropathy, cerebellar ataxia, osteomalacia. Highly protein bound ( 90 % 90\% 90% to albumin).

Carbamazepine : Potent enzyme inducer that exhibits autoinduction of its own CYP3A4-mediated metabolism over the first 2 − 4 weeks 2-4\text{ weeks} 2 − 4 weeks . Adverse effects: hyponatremia (SIADH), aplastic anemia, agranulocytosis, and severe cutaneous adverse reactions (SJS/TEN) strongly linked to the HLA-B*1502 allele in Asian ancestry.

Lamotrigine : Blocks voltage-gated Na + \text{Na}^+ Na + channels and suppresses glutamate release. Metabolized primarily via glucuronidation. Drug Interaction : Valproate potently inhibits lamotrigine glucuronidation, doubling its elimination half-life and drastically increasing SJS risk; lamotrigine starting doses must be reduced by ≥ 50 % \ge 50\% ≥ 50% .

Valproic Acid / Divalproex : Broad-spectrum ASM. Blocks Na + \text{Na}^+ Na + channels, increases GABA levels (inhibits GABA transaminase and succinic semialdehyde dehydrogenase), and blocks T-type Ca 2 + \text{Ca}^{2+} Ca 2 + currents. Adverse effects : Hepatotoxicity, acute pancreatitis, hyperammonemia, weight gain, alopecia, thrombocytopenia, and severe teratogenicity (neural tube defects; avoid in women of childbearing potential).

Ethosuximide : Selectively blocks low-voltage-activated T-type calcium channels in thalamocortical relay neurons, disrupting the synchronized 3 -Hz 3\text{-Hz} 3 -Hz spike-and-wave rhythm of generalized absence seizures .